Report Overview

The Major Depressive Disorders (MDD) Therapeutics market, which covers various forms of depression and seasonal affective disorder, is set to rise from $XX billion in 2019 to $ XX billion by 2028, at a compound annual growth rate of XX%

Depression is treatable, but about 50% of major depressions still go untreated. Depression is a major challenge to all health systems in the EU. Its high personal, social, and economic costs and the high proportion of people not receiving any treatment, despite the availability of cheap and effective care, show that this challenge must be met. Major depressive disorder (MDD), schizophrenia and bipolar I disorder, Obsessive-Compulsive Disorders (OCD), and anxiety disorder are some of the different types of depression. Various drug classes are used to treat depression. Mental disorders account for about 20% of the burden of disease in the European Region, rising to 26% in the countries in the EU. Depression alone is responsible for about 15% of all days lived with a disability



Market Growth Drivers

The prevalence of MDD is expected to increase, mainly due to improving public awareness of depressive disorders, an increase in routine screening, and the rise of stress factors in the EU region. Also, Increased investments in R&D in the pharmaceutical sector and the introduction of innovative drugs have also fueled the growth of the EU market. The ongoing development of drugs with properties, such as improved safety and high patient compliance, are also supporting the growth of the major depressive disorders therapeutics market. Therapies, such as biological therapy, meditation, and physiotherapy, have immense potential to spur the growth of this market